In a significant shift for prenatal care, new research spotlighting the use of cell-free DNA (cfDNA) testing indicates a path forward where precision meets cost-saving, as reported by MIT News. Pivoting away from riskier and more invasive procedures like amniocentesis and chorionic villus sampling (CVS), cfDNA blood tests detect chromosomal variations such as Down Syndrome, offering a safer alternative to many expectant mothers. However, the study emphasizes, precision is key in allocating these tests for maximum benefit without financial excess.
According to MIT economist Amy Finkelstein, a co-author of the study, "What we find is the highest value for the cfDNA testing comes from people who are high risk, but not extraordinarily high risk," pointing out that an indiscriminate application of the technology isn't necessarily the most cost-effective strategy. Examining data from over 230,000 pregnancies between 2011 and 2019 in Sweden, where cfDNA test availability varied regionally, researchers discerned that more targeted use of cfDNA led to significant reductions in invasive testing rates, meanwhile managing to reduce healthcare costs as well.
Interestingly, the two pronged approaches to cfDNA test coverage – whether broad or targeted – equally lowered the rate of invasive testing down to roughly 5 percent, yet their economic impact diverged noticeably. Widespread coverage upped the costs by about $250 per pregnancy, while the targeted approach cut costs by approximately $89 per patient, a clear indicator that informed policy stands at the heart of optimizing both care and expenditure.
"People who are very high-risk are often going to use the invasive test, which is definitive, regardless of whether they have a cfDNA screen or not," Finkelstein said, "But for middle-risk people, covering cfDNA produces a big increase in cfDNA testing, and that produces a big decline in the rates of the riskier, and more expensive, invasive test."; it's apparent that fine-tuning the deployment of cfDNA screenings can strike a balance between caution and cost. The study's broader implication questions the unchecked enthusiasm for precision medicine, suggesting that the technological advancements on their own don't necessarily dial down healthcare spending or guarantee better outcomes without strategic policy intervention.
The study, partly funded by the U.S. National Science Foundation, not only underscores the nuance needed in medical technology application but also exemplifies a smarter approach where diagnostic tools are matched with patient profiles to extract the fullest value. As Petra Persson, assistant professor of economics at Stanford University, succinctly put it, "Sometimes when we think medical technology has an impact, we simply ask if the technology raises or lowers health care costs, or if it makes patients healthier," she observed, "An important insight from our work, I think, is that the answers are not just about the technology. It’s about the pairing of technology and policy because policy is going to influence the impact of technology on health care and patient outcomes." In essence, the research prompts a recalibration: precise medicine, indeed, but precisely applied.
